How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 601–700 of 1,000
Metaphors in Nanomedicine: The Case of Targeted Drug Delivery
Bensaude‐Vincent, B., & Loeve, S. (2013) · NanoEthics · doi:10.1007/s11569-013-0183-5 · Cited by 40
Phenotypic Screens Targeting Neurodegenerative Diseases
Zhang, M., Luo, G., Zhou, Y., Wang, S., & Zhong, Z. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499777 · Cited by 32
Kutilek, V. D., Andrews, C. L., Richards, M. P., Xu, Z., Sun, T., Chen, Y., Hashke, A., Smotrov, N., Fernandez, R., Nickbarg, E. B., et al. (2016) · SLAS Discovery · doi:10.1177/1087057116637353 · Cited by 32
Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury
Skrypnyk, N. I., Sanker, S., Skvarca, L. B., Novitskaya, T., Woods, C., Chiba, T., Patel, K. Y., Goldberg, N. D., McDermott, L. A., Vinson, P. N., et al. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00503.2015 · Cited by 32
Plate-Based Phenotypic Screening for Pain Using Human iPSC-Derived Sensory Neurons
Stacey, P., Wassermann, A. M., Kammonen, L. R., Impey, E., Wilbrey, A. L., & Cawkill, D. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218764678 · Cited by 31
Integration of Lead Discovery Tactics and the Evolution of the Lead Discovery Toolbox
Leveridge, M. V., Chung, C., Gross, J. W., Phelps, C. B., & Green, D. V. S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218778503 · Cited by 33
Highly scalable and standardized organ-on-chip platform with TEER for biological barrier modeling
Nguyen, H.-T., Rissanen, S.-L., Peltokangas, M., Laakkonen, T., Kettunen, J., Barthod, L., Sivakumar, R., Palojärvi, A., Junttila, P., Talvitie, J., et al. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2315702 · Cited by 31
Lifespan extension of rotifers by treatment with red algal extracts
Snare, D. J., Fields, A. M., Snell, T. W., & Kubanek, J. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.09.007 · Cited by 32
Nonconventional chemical inhibitors of microRNA: therapeutic scope
Jayaraj, G. G., Nahar, S., & Maiti, S. (2014) · Chemical Communications · doi:10.1039/c4cc04514a · Cited by 35
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
Waters, N., Tedroff, J., Pontén, H., Klamer, D., Sonesson, C., & Waters, N. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170267 · Cited by 36
Dhole, S., & Sun, C. (2018) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201801241 · Cited by 30
In Silico Drug Design Methods for Drug Repurposing
Akhoon, B. A., Tiwari, H., & Nargotra, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00003-1 · Cited by 37
Paciaroni, N. G., Perry, D. L., Norwood, V. M., Murillo-Solano, C., Collins, J. E., Tenneti, S., Chakrabarti, D., & Huigens, R. W. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00380 · Cited by 30
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
Hajeri, P. B., Sharma, N., & Yamamoto, M. (2020) · Cancers · doi:10.3390/cancers12061504 · Cited by 31
Rothenaigner, I., & Hadian, K. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211008862 · Cited by 32
Thirunavukkarasu, M. K., Suriya, U., Rungrotmongkol, T., & Karuppasamy, R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010059 · Cited by 30
Proteome‐Wide Fragment‐Based Ligand and Target Discovery
Forrest, I., & Parker, C. G. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200098 · Cited by 32
Future directions in phosphodiesterase drug discovery
DeNinno, M. P. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.028 · Cited by 31
Šileikytė, J., & Forte, M. A. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.02.016 · Cited by 33
Systems Biology Approaches to a Rational Drug Discovery Paradigm
Prathipati, P., & Mizuguchi, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114524 · Cited by 35
What general conclusions can we draw from kinase profiling data sets?
Sutherland, J. J., Gao, C., Cahya, S., & Vieth, M. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.023 · Cited by 31
Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 31
Feng, F., Zhang, W., Chai, Y., Guo, D., & Chen, X. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115107 · Cited by 35
Cell morphology-guided de novo hit design by conditioning GANs on phenotypic image features
Zapata, P. A. M., Méndez‐Lucio, O., Le, T., Beese, C. J., Wichard, J., Rouquié, D., & Clevert, D.-A. (2023) · Digital Discovery · doi:10.1039/d2dd00081d · Cited by 40
Label-Free Phenotypic Profiling Identified D-Luciferin as a GPR35 Agonist
Hu, H., Deng, H., & Ye, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034934 · Cited by 29
Translational semantics and infrastructure: another search for the emperor's new clothes?
Mullane, K., & Williams, M. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.004 · Cited by 30
Phenotypic Assessment and the Discovery of Topiramate
Maryanoff, B. E. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00176 · Cited by 32
The Future of Cardiovascular Therapeutics
MacRae, C. A., Roden, D. M., & Loscalzo, J. (2016) · Circulation · doi:10.1161/circulationaha.116.023555 · Cited by 30
Thomas, J. R., Brittain, S. M., Lipps, J., Llamas, L., Jain, R. K., & Schirle, M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7201-2_1 · Cited by 29
Grienke, U., Mair, C. E., Kirchmair, J., Schmidtke, M., & Rollinger, J. M. (2018) · Planta Medica · doi:10.1055/a-0590-5153 · Cited by 29
Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry
Sweis, R. F. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00183 · Cited by 29
An explainable deep learning platform for molecular discovery
Wong, F. J., Omori, S., Li, A., Krishnan, A., Lach, R. S., Rufo, J., Wilson, M. Z., & Collins, J. J. (2024) · Nature Protocols · doi:10.1038/s41596-024-01084-x · Cited by 32
From noncovalent to covalent bonds: a paradigm shift in target protein identification
Park, J., Koh, M., & Park, S. B. (2012) · Molecular BioSystems · doi:10.1039/c2mb25502b · Cited by 32
McGivern, J. V., & Ebert, A. D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.012 · Cited by 30
Machine Learning in Mass Spectrometry: A MALDI-TOF MS Approach to Phenotypic Antibacterial Screening
van Oosten, L. N., & Klein, C. D. P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00040 · Cited by 28
Seneviratne, U. I., Huang, Z., Ende, C. W. A., Butler, T. W., Cleary, L., Dresselhaus, E. C., Evrard, E., Fisher, E. L., Green, M. E., Helal, C. J., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.09.002 · Cited by 30
Fast Nanoliter‐Scale Cell Assays Using Droplet Microarray–Mass Spectrometry Imaging
Guevara, C. R., Paulssen, D., Popova, A. A., Hopf, C., & Levkin, P. A. (2021) · Advanced Biology · doi:10.1002/adbi.202000279 · Cited by 29
Late-Stage 18F/19F Isotopic Exchange for the Synthesis of 18F-Labeled Sulfamoyl Fluorides
Jeon, M. H., Kwon, Y., Kim, M. P., Torres, G. B., Seo, J. K., Son, J., Ryu, Y. H., Hong, S. Y., & Chun, J. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c00671 · Cited by 29
Industrializing AI/ML during the end-to-end drug discovery process
Yoo, J., Kim, T. Y., Joung, I., & Song, S. O. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102528 · Cited by 33
An analysis of FDA-approved drugs for neurological disorders
Kinch, M. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.003 · Cited by 28
Label-free monitoring of T cell activation by the impedance-based xCELLigence system
Guan, N., Deng, J., Li, T., Xu, X., Irelan, J. T., & Wang, M. (2013) · Molecular BioSystems · doi:10.1039/c3mb25421f · Cited by 29
Chattopadhyay, S., Stewart, A. L., Mukherjee, S., Huang, C., Hartwell, K. A., Miller, P. G., Subramanian, R., Carmody, L., Yusuf, R. Z., Sykes, D. B., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.017 · Cited by 33
Centralized mouse repositories
Donahue, L. R., de Angelis, M. H., Hagn, M., Franklin, C. L., Lloyd, K. C. K., Magnuson, T., McKerlie, C., Nakagata, N., Obata, Y., Read, S., et al. (2012) · Mammalian Genome · doi:10.1007/s00335-012-9420-4 · Cited by 27
Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits
Blaazer, A. R., Orrling, K. M., Shanmugham, A., Jansen, C., Maes, L. J. R. M., Edink, E., Sterk, G. J., Siderius, M. H., ENGLAND, P. J., Bailey, D. S., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114549735 · Cited by 33
Kiris, E., Kota, K. P., Burnett, J. C., Soloveva, V., Kane, C. D., & Bavari, S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.867808 · Cited by 33
Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations
Dragovich, P. S., Haap, W. J., Mulvihill, M. M., Plancher, J., & Stepan, A. F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02106 · Cited by 30
Deep Learning in Cell Image Analysis
Xu, J., Zhou, D., Deng, D., Li, J., Chen, C., Liao, X., Chen, G., & Heng, P. (2022) · Intelligent Computing · doi:10.34133/2022/9861263 · Cited by 35
Advances in application and innovation of microfluidic platforms for pharmaceutical analysis
Ma, L., Li, N., Wang, J., Ma, C., Hu, X., Li, M., & Wu, Z. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.116951 · Cited by 27
How can we discover developable antibody-based biotherapeutics?
Bauer, J., Rajagopal, N., Gupta, P., Gupta, P. K., Nixon, A. E., & Kumar, S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1221626 · Cited by 29
Paquet, T., Gordon, R. K., Waterson, D., Witty, M. J., & Chibale, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.176 · Cited by 27
Elebring, T., Gill, A. L., & Plowright, A. T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.009 · Cited by 31
Wang, D., Feng, Y., Murtaza, M., Wood, S. A., Mellick, G. D., Hooper, J. N. A., & Quinn, R. J. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00987 · Cited by 28
Hosoya, M., & Czysz, K. (2016) · Cells · doi:10.3390/cells5040046 · Cited by 27
Grixti, J. M., O’Hagan, S., Day, P. J., & Kell, D. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00155 · Cited by 27
Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening
Zheng, X. T., Goh, W. L., Yeow, P., Lane, D. P., Ghadessy, F. J., & Tan, Y. N. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.09.088 · Cited by 27
Park, H., & Park, S. B. (2019) · Chemical Science · doi:10.1039/c8sc05465g · Cited by 27
Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs
Bulterijs, S., & Braeckman, B. P. (2020) · Pharmaceuticals · doi:10.3390/ph13080164 · Cited by 33
Costantino, L., & Barlocco, D. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.193 · Cited by 28
Butera, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400443k · Cited by 27
Ferreira, L. L. G., Oliva, G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170505 · Cited by 27
Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration
Morizur, L., Herardot, E., Monville, C., & M’Barek, K. B. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103523 · Cited by 33
Burton, E. A., & Burgess, H. A. (2022) · Oxford Open Neuroscience · doi:10.1093/oons/kvac019 · Cited by 27
Discovery of novel drug targets and their functions using phenotypic screening of natural products
Chang, J., & Kwon, H. J. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1681-y · Cited by 27
Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets
Fernandes, G., Jornada, P. D., de Souza, C. O., Chin, C. M., Pavan, F. R., & dos Santos, J. L. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150818103836 · Cited by 30
Cancer drug discovery: recent innovative approaches to tumor modeling
Lovitt, C. J., Shelper, T., & Avery, V. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1214562 · Cited by 31
Dovrolis, N., Kolios, G. C., Spyrou, G. M., & Maroulakou, I. G. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.009 · Cited by 31
Saei, A. A., Sabatier, P., Güler, Ü., Chernobrovkin, A. L., Pirmoradian, M., & Zubarev, R. A. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000610 · Cited by 29
Jiao, Y., Preston, S., Hofmann, A., Taki, A. C., Baell, J. B., Chang, B. C. H., Jabbar, A., & Gasser, R. B. (2020) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2019.12.003 · Cited by 35
Formatting biological big data for modern machine learning in drug discovery
Duran‐Frigola, M., Fernández‐Torras, A., Bertoni, M., & Aloy, P. (2019) · WIREs Computational Molecular Science · doi:10.1002/wcms.1408 · Cited by 25
Palmér, T., Ek, F., Enqvist, O., Olsson, R., Åström, K., & Petersson, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-03144-7 · Cited by 31
Hydration of Aromatic Heterocycles as an Adversary of π-Stacking
Loeffler, J. R., Schauperl, M., & Liedl, K. R. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00395 · Cited by 25
Identification and Development of Therapeutics for COVID-19
Rando, H. M., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., Byrd, J. B., Rafizadeh, D. N., Lordan, R., Qi, Y., et al. (2021) · mSystems · doi:10.1128/msystems.00233-21 · Cited by 28
Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study
Atkinson, E. L., Iegre, J., Brear, P., Zhabina, E. A., Hyvönen, M., & Spring, D. R. (2021) · Molecules · doi:10.3390/molecules26071977 · Cited by 25
Drug Target Identification with Machine Learning: How to Choose Negative Examples
Najm, M., Azencott, C., Playe, B., & Stoven, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105118 · Cited by 28
Mol2Image: Improved Conditional Flow Models for Molecule to Image Synthesis
Yang, K., Goldman, S., Jin, W., Lu, A. X., Barzilay, R., Jaakkola, T., & Uhler, C. (2021) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr46437.2021.00662 · Cited by 33
A high-throughput assay for quantifying appetite and digestive dynamics
Jordi, J., Guggiana-Nilo, D., Soucy, E. R., Song, E. Y., Wee, C. L., & Engert, F. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00225.2015 · Cited by 30
Droplet microarray platforms for high-throughput drug screening
Shi, L., Liu, S., Li, X., Huang, X., Luo, H., Bai, Q., Li, Z., Wang, L., Du, X., Jiang, C., et al. (2023) · Microchimica Acta · doi:10.1007/s00604-023-05833-9 · Cited by 29
Scalable, compressed phenotypic screening using pooled perturbations
Liu, N., Kattan, W. E., Mead, B. E., Kummerlowe, C., Cheng, T. N. H., Ingabire, S., Cheah, J. H., Soule, C. K., Vrcic, A., McIninch, J. K., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02403-z · Cited by 37
Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease
Tardiff, D. F., & Lindquist, S. L. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.02.003 · Cited by 25
Geerts, H., Roberts, P., Spiros, Ä., & Carr, R. A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00047 · Cited by 27
Phenotypic assays for analyses of pluripotent stem cell–derived cardiomyocytes
Pešl, M., Přibyl, J., Caluori, G., Čmiel, V., Aćimović, I., Jelínková, Š., Dvořák, P., Stárek, Z., Skládal, P., & Rotrekl, V. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2602 · Cited by 27
He, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-07748-x · Cited by 25
Chrétien, B., Jourdan, J., Davis, A., Fédrizzi, S., Bureau, R., Sassier, M., Rochais, C., Alexandre, J., Lelong‐Boulouard, V., Dolladille, C., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14690 · Cited by 26
Anti-cancer potential of natural products: recent trends, scope and relevance
(2020) · Letters in Applied NanoBioScience · doi:10.33263/lianbs91.902907 · Cited by 25
Academic drug discovery within the United Kingdom: a reassessment
Shanks, E. J., Ketteler, R., & Ebner, D. V. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4661 · Cited by 25
Assessing the performance of the Cell Painting assay across different imaging systems
Tromans‐Coia, C., Jamali, N., Abbasi, H. S., Giuliano, K. A., Hagimoto, M., Jan, K., Kaneko, E., Letzsch, S., Schreiner, A., Sexton, J. Z., et al. (2023) · Cytometry Part A · doi:10.1002/cyto.a.24786 · Cited by 24
Beierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
“All biologics were classified as targeted, consistent with Swinney(52) and Swinney and Anthony.(53) The clinical entry date was determined for 151 of 168 NMEs as the date of first testing in humans ascertained from Tufts Center for Study of Drug Development,(21,54) clinical trial dates in Pharmaprojects,(51) or litera…”
BackgroundMethodA New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
Kopp, K. O., Greer, M. E., Glotfelty, E. J., Hsueh, S., Tweedie, D., Kim, D. S., Reale, M., Vargesson, N., & Greig, N. H. (2023) · Biomolecules · doi:10.3390/biom13050747 · Cited by 26
Liang, H., Feng, Y., Zeng, D., Zhang, J., Cheng, L., Fu, X., Long, Z., Zhou, X., Liu, L., Wu, Z., et al. (2025) · Pest Management Science · doi:10.1002/ps.8793 · Cited by 26
Dhole, S., Selvaraju, M., Maiti, B., Chanda, K., & Sun, C. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00010 · Cited by 24
Glial cells as drug targets: What does it take?
Möller, T., & Boddeke, H. W. G. M. (2016) · Glia · doi:10.1002/glia.22993 · Cited by 25
Jang, J.-W., Song, Y., Kim, K. M., Kim, J.-S., Choi, E. K., Kim, J., & Seo, H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2816-x · Cited by 24
Translating Knowledge Into Therapy for Acute Kidney Injury
deCaestecker, M. P., & Harris, R. C. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2017.09.008 · Cited by 24
Filling the drug discovery gap: is high-content screening the missing link?
Dorval, T., Chanrion, B., Cattin, M., & Stephan, J. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.002 · Cited by 26
Choi, Y., Kim, H., & Park, S. B. (2018) · Chemical Science · doi:10.1039/c8sc04061c · Cited by 24
Addressing Antimicrobial Resistance through New Medicinal and Synthetic Chemistry Strategies
Konaklieva, M. I. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218812657 · Cited by 25
Byrne, F. L., Olzomer, E. M., Marriott, G. R., Quek, L., Katen, A., Su, J., Nelson, M. E., Hart‐Smith, G., Larance, M., Sebesfi, V. F., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101374 · Cited by 24
Hughes, R. E., Elliott, R. J. R., Li, X., Munro, A. F., Makda, A., Carter, R. N., Morton, N. M., Fujihara, K. M., Clemons, N. J., Fitzgerald, R. C., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00301 · Cited by 26
Stability-based approaches in chemoproteomics
George, A. L., Dueñas, M. E., Marín‐Rubio, J. L., & Trost, M. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.6 · Cited by 26
Target‐Based Whole‐Cell Screening by 1H NMR Spectroscopy
Ma, J., Cao, Q., McLeod, S. M., Ferguson, K., Gao, N., Breeze, A. L., & Hu, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410701 · Cited by 24
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.